Scholarlink

<p>Atrial fibrillation (AF) is the most common sustained arrhythmia and a leading cause of ischemic stroke. Existing risk scores, such as CHA₂DS₂-VASc, offer limited predictive accuracy and fail to capture complex clinical patterns. To improve generalizability and clinical utility, we developed and externally validated clinically interpretable machine learning models using only age, comorbidities, and medication use to predict 1-year stroke risk in patients with newly diagnosed AF. Both logistic regression (LR) and Platt-calibrated extreme gradient boosting (XGB) models achieved high discrimination in internal (AUCs = 0.915 and 0.914) and external validation cohorts (AUCs = 0.877–0.886), significantly outperforming CHA₂DS₂-VASc (AUCs = 0.614–0.621; <i>p</i> &lt; 0.001). Calibration curves and decision curve analysis confirmed strong clinical utility. Long-term follow-up demonstrated superior risk stratification and treatment responsiveness in LR-defined high-risk groups. These models provide accurate, individualized stroke risk estimates to guide direct oral anticoagulant (DOAC) initiation in real-world hospital settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interpretable machine learning models for stroke risk prediction in patients with newly diagnosed atrial fibrillation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月7日

查看全文
  • Jesse Chih-Wei Lin,
  • Chen-Min Chang,
  • Heng-Yu Pan,
  • Yi-Lwun Ho,
  • Yu-Kang Tu,
  • Chao-Lun Lai

摘要

Atrial fibrillation (AF) is the most common sustained arrhythmia and a leading cause of ischemic stroke. Existing risk scores, such as CHA₂DS₂-VASc, offer limited predictive accuracy and fail to capture complex clinical patterns. To improve generalizability and clinical utility, we developed and externally validated clinically interpretable machine learning models using only age, comorbidities, and medication use to predict 1-year stroke risk in patients with newly diagnosed AF. Both logistic regression (LR) and Platt-calibrated extreme gradient boosting (XGB) models achieved high discrimination in internal (AUCs = 0.915 and 0.914) and external validation cohorts (AUCs = 0.877–0.886), significantly outperforming CHA₂DS₂-VASc (AUCs = 0.614–0.621; p < 0.001). Calibration curves and decision curve analysis confirmed strong clinical utility. Long-term follow-up demonstrated superior risk stratification and treatment responsiveness in LR-defined high-risk groups. These models provide accurate, individualized stroke risk estimates to guide direct oral anticoagulant (DOAC) initiation in real-world hospital settings.